Ampio Presents at Roth Capital Partners 2020 MedTech Innovation Forum Focusing on COVID-19 Clinical Trial Activities
Ampio Pharmaceuticals (AMPE) announced its participation in the 2020 MedTech Innovation Forum on October 28. The presentation will focus on preliminary results from a randomized study assessing the efficacy of Ampion in hospitalized COVID-19 patients requiring supplemental oxygen. The study compared Ampion plus standard of care (SOC) against SOC alone and SOC with remdesivir. Results showed that Ampion improved average outcomes significantly, with a reduction of 3 points in the Ordinal Scale compared to lesser reductions in the other groups. The primary endpoint of safety also reported no drug-related adverse events.
- Ampion demonstrated improved average outcomes for COVID-19 patients, reducing the Ordinal Scale score by 3 points compared to 1.5 and 2.25 for SOC alone and SOC plus remdesivir, respectively.
- No drug-related adverse events reported during a 5-day post-treatment period, indicating safety of the treatment.
- None.
ENGLEWOOD, Colo., Oct. 26, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the Company will present at the 2020 MedTech Innovation Forum hosted by Roth Capital Partners on Wednesday, October 28, 2020.
The Company's presentation will (i) review preliminary results from the randomized, controlled study of intravenous Ampion™ for treatment of hospitalized COVID-19 infected adult patients requiring supplemental oxygen and (ii) further discuss its future COVID-19 plans. Ampion addition to standard of care ("SOC") was compared to patients treated with the SOC including anti-viral therapy ("remdesivir"). Safety was determined by presence of adverse events during the trial and indications of efficacy was determined by the Ordinal Scale, a measure developed by the WHO (a range of 0-8, with 0 defined as uninfected with no clinical or virological signs of infection and 8 denoting death) and calculated as a change from admission to discharge or at the time of discharge from the hospital.
The primary end-point was safety and, as previously reported, there were no drug related adverse events for a period of 5 days subsequent to the treatment with Ampion. The secondary end point was improvement in the score as measured by the Ordinal Scale. Ampion addition to the SOC compared to the SOC alone or SOC plus remdesivir, demonstrated that the addition of Ampion to the SOC resulted in better average outcomes (reduction in 3 points for Ampion+ SOC versus 1.5 and 2.25 points for SOC and SOC+remdesivir, respectively). Average scores as measured by the Ordinal Scale at the time of discharge from the hospital were also better for Ampion+SOC compared to the other groups (a score of 1 for Ampion +SOC versus 2.75 and 1.75 for SOC and SOC+remdesivir, respectively).
About Ampio Pharmaceutical
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of Ampion, our product candidate, to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio's lead drug, Ampion, is backed by an extensive patent portfolio with intellectual property protection extending through 2032, and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act ("BPCIA").
Forward Looking Statements
Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application ("BLA"), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
Dan Stokely, CFO
Phone: (720) 437-6500
info@ampiopharma.com
Ampio Pharmaceuticals, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ampio-presents-at-roth-capital-partners-2020-medtech-innovation-forum-focusing-on-covid-19-clinical-trial-activities-301159523.html
SOURCE Ampio Pharmaceuticals, Inc.
FAQ
What were the results of the Ampion study presented at the 2020 MedTech Innovation Forum?
What is Ampion used for?
What is the next step for Ampio Pharmaceuticals regarding Ampion?
When is Ampio's presentation at the MedTech Innovation Forum?
What safety results were reported for Ampion in the trial?
